In cBAF-deficient cancer cells, inhibition of CBP/p300 leads to marked repression of KREMEN2, which reduces cell viability; this suggests that expression of the KREMEN2 gene is induced cooperatively by CBP and p300 and that it is required for the viability of cBAF-deficient cells. This evidence concerns the gene EP300 and cancer.